News
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...
The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...
Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...
Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...
3h
Zacks Investment Research on MSNIs Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...
Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...
Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...
Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results